arrow
J

Jonathan Chou

University of California San Francisco
H指数:33
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer

自噬溶酶体胞吐作用将Src激酶反转到癌症的细胞表面

Science
IF45.8
2026-03-120
PRE
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

基因组规模CRISPR筛选确定PTGES3为晚期前列腺癌雄激素受体功能的直接调节因子

2025-11-050
OAAI
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

通过调节PPARγ通路上调NECTIN4,并增强膀胱癌中嵌合抗原受体(CAR)T细胞疗法。Nat. Commun. 16 (1), 8215

2025-09-100
OAAI
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
2024-10-010
OAAI
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
2024-09-271
OAAI
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024-09-251
PRE
CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality
2024-06-100
PRE
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
2024-05-245
PRE
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2023-06-0817
OAAI
Genomic and epigenomic drivers of double-negative metastatic prostate cancer
2023-06-020
PRE
Genome-wide CRISPR screens identify PTGES3 as a druggable AR modulator
2023-06-020
PRE
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

TP53和MDM2的体细胞改变与晚期尿路上皮癌患者对enfortumab vedotin的反应相关

2023-04-058
OAAI